×

Endocyte Announces Poster Presentations on Vintafolide and Etarfolatide at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO)

WEST LAFAYETTE, Ind., May 30, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's investigational cancer candidate, vintafolide (EC145) and its non-invasive, companion diagnostic imaging agent, etarfolatide (EC20) will be featured at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, May 31 to June 4.

The presentations are as follows:

Abstract: TPS8125
Title: A randomized, open-label phase II study of single-agent vintafolide versus vintafolide plus docetaxel versus docetaxel alone in second-line NSCLC patients with all target lesions expressing folate-receptor (TARGET).
When: Saturday, June 1, 8 to 11:45 a.m. CDT
Abstract: TPS5613
Title: A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).
When: Monday, June 3, 8 to 11:45 a.m. CDT
Abstract: 5572
Title: Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.
When: Monday, June 3, 8 to 11:45 a.m. CDT

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, martina.schwarzkopf@russopartnersllc.com Tony Russo, Ph.D., Russo Partners, (212) 845-4251, tony.russo@russopartnersllc.comSource:Endocyte, Inc.